Compare NOTV & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOTV | VNRX |
|---|---|---|
| Founded | 1974 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 38.2M |
| IPO Year | 1997 | N/A |
| Metric | NOTV | VNRX |
|---|---|---|
| Price | $0.76 | $0.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $3.17 |
| AVG Volume (30 Days) | 1.6M | ★ 2.8M |
| Earning Date | 12-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $513,024,000.00 | $1,472,007.00 |
| Revenue This Year | $6.26 | $55.33 |
| Revenue Next Year | $45.49 | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.54 | ★ 14.48 |
| 52 Week Low | $0.66 | $0.27 |
| 52 Week High | $6.48 | $0.94 |
| Indicator | NOTV | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.16 | 31.94 |
| Support Level | $0.79 | $0.28 |
| Resistance Level | $0.86 | $0.31 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 3.93 | 3.40 |
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.